SEC Form 4 · accession 0001209191-19-016931
Denali Therapeutics Inc. · DNLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ryan J. Watts
Officer — President and CEO · Director
Period of report
Mar 1, 2019
Accepted (ET)
Mar 5, 2019 · 6:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001714899
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Mar 1, 2019 | S | 4,000 | $22.19 | D | 2,630,304 | I | See footnote |
| Common StockF4,F3 | Mar 1, 2019 | S | 2,050 | $22.91 | D | 2,628,254 | I | See footnote |
| Common StockF5,F3 | Mar 4, 2019 | S | 4,442 | $21.87 | D | 2,623,812 | I | See footnote |
| Common StockF6,F3 | Mar 4, 2019 | S | 1,700 | $22.83 | D | 2,622,112 | I | See footnote |
| Common StockF7,F3 | Mar 5, 2019 | S | 6,141 | $21.97 | D | 2,615,971 | I | See footnote |
| Common Stock | holding | — | — | — | 12,505 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- F2The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $21.76 to $22.75 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F3The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
- F4The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $22.82 to $23.03 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F5The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $21.54 to $22.28 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F6The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $22.61 to $23.17 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F7The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $21.42 to $22.32 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.